Proteomics International Laboratories testing using its “PromarkerD” device that employs a simple blood test has shown a high accuracy in being able to predict future kidney disease in type 1 diabetes patients.
The company has told this week’s Australasian Diabetes Conference in Perth that testing has confirmed its excellent predictive qualities in detecting the possibility of future renal decline, marking the first time it has shown potential for forecasting chronic kidney disease (CKD) in type 1 patients. The tests indicate that PromarkerD is at least as good at predicting renal decline in type 1 patients as it is for those living with the type 2 version of the widespread disease.
